• Home
• About
  • Overview
  • Management Team
  • Board of Directors
  • Clinical Advisory Board
  • Business Development
• Science
  • Overview
  • Publications
• Therapeutic Targets
  • Pipeline
  • Wound Healing
  • Myocardial Infarction
  • Stroke
  • Cartilage / Bone
• Contact Us
• Download Our Corporate Profile (PDF)

Board of Directors

Barry Dickman

Mr. Dickman joined the Board of Directors of GliaMed in June 2008 as the representative of Quantum Technology Partners. Currently Mr. Dickman is Chairman and CEO of the GliaMed and is the founder and managing general partner of Quantum. In addition to GliaMed, Mr. Dickman is responsible for Quantum’s investments in BiPar Sciences, an oncology company acquired by sanofi-aventis in 2Q2009; Vaxart, an oral vaccine delivery company; IMI Devices, developing an implantable device for treating blindness; Peri-Ness, a company developing a therapy for male infertility; and Corium, a transdermal delivery technology and product company.

Prior to founding Quantum, Mr Dickman spent more than 25 years in technology and executive management positions. During this time he was founder and/or CEO of three technology companies which were acquired or went public. He also held senior management positions at Autodesk and Exxon Enterprise and has consulted for major corporations including News Corporation, HBO, DEC, Eastman Kodak and Adobe Systems.

Andrew L. Busser

Mr. Busser is a cofounder and principal of Symphony Capital LLC. He has spent more than 15 years in the biotechnology and pharmaceutical industry and was a management consultant with The Wilkerson Group/IBM Healthcare Consulting prior to co-founding Wilkerson Partners. Earlier in his career, Mr. Busser worked in sales and marketing management at Dupont Merck Pharmaceutical Company. He is presently Chairman of the Board of Directors of Symphony Allegro, one of Symphony Capital’s portfolio companies.

David E. Weinstein, M.D., Ph.D.

Dr. Weinstein is the Founder and Chief Scientific Officer of GliaMed, and was formerly a professor in the Departments of Neuroscience and Pathology at the Albert Einstein College of Medicine. He is an internationally recognized expert in the areas of multiple sclerosis, brain tumor research and spinal cord and nerve regeneration, and has served as a consultant and advisor to both the NIH and the WHO, as well as to a number of scientific research organizations including the Children’s Brain Tumor Foundation, the Christopher Reeves Paralysis Foundation, the Paralyzed Veterans of America/Spinal Cord Research Foundation and the National Multiple Sclerosis Foundation.